New drug cocktail aims to wipe out hidden myeloma cells after transplant
NCT ID NCT04876248
First seen Nov 10, 2025 · Last updated Apr 28, 2026 · Updated 22 times
Summary
This study tests whether a combination of belantamab mafodotin (a targeted chemotherapy) and lenalidomide can eliminate leftover cancer cells in multiple myeloma patients who still have signs of disease after a stem cell transplant. The goal is to achieve a state called minimal residual disease negativity, meaning no detectable cancer cells. The trial enrolls adults aged 18 and older with good performance status.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLASMA CELL MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
Conditions
Explore the condition pages connected to this study.